Egress: A receptor-regulated step in lymphocyte trafficking

Immunological Reviews

Volumn 195, Issue , 2003, Pages 160-177

  Rosen, Hugh ^a   Sanna, Germana ^a   Alfonso, Christopher ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; FINGOLIMOD; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHOLIPID; NITRIC OXIDE; PHOSPHONIC ACID DERIVATIVE; SPHINGOSINE 1 PHOSPHATE;

ANTIGEN PRESENTING CELL; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BINDING AFFINITY; BONE MARROW; CARDIOVASCULAR SYSTEM; CELL DIVISION; CELL FUNCTION; CELL MIGRATION; DENDRITIC CELL; DYSLIPIDEMIA; FIBROBLAST; IMAGE CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOCYTOPENIA; LYMPHOID ORGAN; LYMPHOPOIESIS; MASS SPECTROMETRY; MESENTERY LYMPH NODE; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PEYER PATCH; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SPLEEN; T LYMPHOCYTE; THYMUS; TISSUE INJURY; TRANSPLANTATION; VIRUS INFECTION;

ANIMALS; CELL MOVEMENT; HUMANS; LYMPH NODES; LYMPHOCYTES; LYMPHOID TISSUE; PROPYLENE GLYCOLS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHOLIPID; SPHINGOSINE;

EID: 0141566600     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00068.x     Document Type: Review

References (117)

1. Gowans JL, Uhr JW. The carriage of immunological memory by small lymphocytes in the rat. J Exp Med 1966;124:1017-1030.
2. Gowans JL. Life-span, recirculation, and transformation of lymphocytes. Int Rev Exp Pathol 1966;5:1-24.
3. Gowans JL. Lymphocytes. Harvey Lect 1969;64:87-119.
4. Gowans JL. Cellular events during the induction of immune responses. Int Arch Allergy Appl Immunol 1971;41:1-3.
5. Gowans JL. The origin and development of lymphocytes. J Reticuloendothel Soc 1975;17:97-98.
6. Gowans JL. Cellular mediators of allograft immunity. Transplant Proc 1977;9:685-690.
7. Gowans JL, Steer HW. The function and pathways of lymphocyte recirculation. Ciba Found Symp 1980;71:113-126.
8. Gowans JL. First Medawar prize lecture. The recirculating small lymphocyte. Transplant Proc 1991;23:7-38.
9. Gowans JL. The lymphocyte - a disgraceful gap in medical knowledge. Immunol Today 1996;17:288-291.
10. Ford WL, Gowans JL. The role of lymphocytes in antibody formation. The influence of lymphocyte migration on the initiation of antibody formation in the isolated, perfused spleen. Proc R Soc Lond B Biol Sci 1967;168:244-262.
11. Ford WL, Gowans JL. The traffic of lymphocytes. Semin Hematol 1969;6:67-83.
12. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998;282:480-483.
13. Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM, Muller WA. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci USA 1998;95:6924-6929.
14. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999;11:753-761.
15. Randolph GJ. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Immunology 2001;13:267-274.
16. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-1033.
17. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE1, Shaw S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med 2000;192:1425-1439.
18. + T-cells. J Exp Med 2001;194:1-15.
19. Mackay CR, Marston WE, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med 1990;171:801-807.
20. Butcher EC, williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-253.
21. Elewaut D, Brossay L, Santee SM, Naidenko OV, Burdin N, De Winter H, Matsuda J, Ware CF, Cheroutre H, Kronenberg M. Membrane lymphotoxin is required for the development of different subpopulations of NK T cells. J Immunol 2000;165:671-679.
22. Leishman AJ, et al. T cell responses modulated through interaction between CD8alpha alpha and the nonclassical MHC class I molecule, TL. Science 2001;294:1936-1939.
23. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
24. Cyster JG. Leukocyte migration: scent of the T zone. Curr Biol 2000;10:R30-R33.
25. Cyster JG. Chemorepulsion and thymocyte emigration. J Clin Invest 2002;109:1011-1012.
26. Ueno T, et al. Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity 2002;16:205-218.
27. Campbell JJ, Pan J, Butcher EC. Cutting edge: developmental switches in chemokine responses during T cell maturation. J Immunol 1999;163:2353-2357.
28. Forster R, Schubel A, Breitfeld D, Kemmer E, Reuner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33.
29. Ansel KM, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol 2001;13:172-179.
30. Poznansky MC, et al. Thymocyte emigration is mediated by active movement away from stroma-derived factors. J Clin Invest 2002;109:1101-1110.
31. Azzali G, Arcari ML. Ultrastructural and three dimensional aspects of the lymphatic vessels of the absorbing peripheral lymphatic apparatus in Peyer's patches of the rabbit. Anat Rec 2000;258:71-79.
32. Cinamon G, Shinder V, Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001;2:515-522.
33. Olah I, Rohlich P, Toro I. Ultrastructure of Lymphoid Organs. Philadelphia: L.B. Lippincott Co. 1975.
34. Nolte M, Hamann A, Kraal G, Mebius R. The strict regulation of lymphocyte migration to splenic white pulp does not involve common homing receptors. Immunology 2002;106:299-307.
35. Lo CG, Lu TT, Cyster JG. Integrin-dependence of lymphocyte entry into the splenic white pulp. J Exp Med 2003;197:353-361.
36. Yednock T, Butcher E, Stoolman L, Rosen S. Receptors involved in lymphocyte homing, relationship between a carbohydrate-binding receptor and the MEL-14 antigen. J Cell Biol 1987;104:725-731.
37. Rosen H, Gordon S. Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo. J Exp Med 1987;166:1685-1702.
38. Rosen H, Milon G, Gordon S. Antibody to the murine type 3 complement receptor inhibits T lymphocyte-dependent recruitment of myelomonocytic cells in vivo. J Exp Med 1989;169:535-548.
39. Rosen H, Gordon S, North R. Exacerbation of murine listeriosis by a monoclonal antibody specific for the type 3 complement receptor of myelomonocytic cells. J Exp Med 1989;170:27-37.
40. Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000;21:49-52.
41. Fujita T, et al. Simple compounds, 2-alkyl-2-amino-1,3-propanediaols have potent immunosuppressive activity. Bioorg Med Chem Lett 1995;5:847-852.
42. Fujita T, et al. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols. J Med Chem 1996;39:4451-4459.
43. Kiuchi M, et al. Synthesis and biological evaluation of 2, 2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg Med Chem Lett 1998;8:101-106.
44. Kiuchi M, et al. Synthesis and immunosuppressive activity of 2-substituted 2-amino propane-1, 3-diols and 2-aminoethanols. J Med Chem 2000;43:2946-2961.
45. Chiba K, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-5044.
46. Chiba K, Yanagawa Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Transplant Proc 1999;31:1230-1233.
47. Chiba K, et al. FTY720, a novel irnmunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996;28:1056-1059.
48. Chueh SC, Tian L, Wang M, Wang ME, Stepkowski SM, Kahan BD. Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720. Transplantation 1997;64:1407-1414.
49. Chueh S, Tsai C, Ckiu B, Li Y, Lai M. Rescuing acute rejection of rat cardiac allografts with FTY720. Transplant Proc 2000;32:1629-1630.
50. Chueh S, Chen J, Chen J, Lai M. FTY720 prevents chronic rejection of rat heterotopic cardiac allografts. Transplant Proc 2001;33:542-543.
51. Suzuki T, et al. Dose-dependent study of novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. Transplant Proc 1999;31:1208-1209.
52. Suzuki S, et al. An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation. Transpl Int 1998;11:95-101.
53. Quesniaux VFJ, et al. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral (R) or with RAD. Transpl Immunol 2000;8:177-187.
54. Brinkmann V, Lynch K. FTY720: targeting G-protein coupled receptors for spingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002;14:569-575.
55. Brunkhorst R, et al. Human safety and pharmacology of FTY 720. Transplantation 1999;67:S153.
56. Budde K, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;13: 1073-1083.
57. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164:5761-5770.
58. Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-niduced arthritis in rats. Int J Immunol 2000;22:323-331.
59. Matsuura M, Imayoshi T, Chiba K, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 2000;49:404-410.
60. Brinkmann V, Chen S, Pinschewer D, Nikolova Z, Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transpl Proc 2001;33:530-531.
61. Fujino M, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003;305:70-77.
62. Brinkmarm V, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-21457.
63. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002;110:3-8.
64. Mandala S, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349.
65. Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001;293:702-705.
66. 4 transporter MRP1 regulates CCL19 (MIP-3B, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000;103:757-768.
67. Yatomi Y, et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000;96:3431-3438.
68. Chun J, et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002;54:265-269.
69. Lynch KR. Lysophospholipid receptor nomenclature. Biochim Biophys Acta 2002;1582:70-71.
70. Fukushima N, Ishii I, Contos JJA, Weiner JA, Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 2001;41:507-534.
71. Hla T, Lee M-J, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids: receptor revelations. Science 2001;294:1875-1878.
72. Spiegel S. Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors. Ann N Y Acad Sci 2000;905:54-60.
73. Van Brocklyn JR, Spiegel S. Binding of sphingosine 1-phosphate to cell surface receptors. Methods Enzymol 2000;312:401-406.
74. Graeler MH, Bernhardt G, Lipp M. A lympoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. Curr Top Microbiol Immunol 1999;246:131-136.
75. Im DS, et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem 2000;275:14281-14286.
76. Dolezalova H, Shankar G, Huang M, Bikle D, Goetzl E. Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate. J Cell Biochem 2003;88:732-743.
77. Huang M, Grader M, Shankar G, Spencer J, Goetzl E. Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta 2002;1582:161-167.
78. Graeler M, Goetzl E. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 2002;16:1874-1878.
79. Graeler M, Shankar G, Goetzl E. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J Immunol 2002;169:4084-4087.
80. Graler M, Goetzl E. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 2002;1582:168-174.
81. Ancellin N, Hla T. Switching intracellular signaling pathways to study sphingosine 1-phosphate receptors. Ann N Y Acad Sci 2000;905:260-262.
82. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000;349:385-402.
83. Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 1999;253:230-238.
84. Wells CD, Gutowski S, Bollag G, Sternweis PC. Identification of potential mechanisms for regulation of p115 RhoGEF through analysis of endogenous and mutant forms of the exchange factor. J Biol Chem 2001;276:28897-28905.
85. Liliom K, et al. Sphingosylyphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 2001;355:189-197.
86. Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 2000;46:119-125.
87. Liu Y, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106:951-961.
88. Allende ML, Proia RL. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002;1582:222-227.
89. Hobson JP, et al. Role of the sphingosine 1-phosphate receptor EDG1 in PDGF-induced cell motility. Science 2001;291:1800-1803.
90. Igarashi J, Michel T. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. J Biol Chem 2000;275:32363-32370.
91. Igarashi J, Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase β. J Biol Chem 2001; 276:36281-36288.
92. Neumayer HH, et al. Human pharmacokinetics of FTY 720. Transplantation 1999;67:S204.
93. Parrill AL, et al. Identification of Edg1 receptor residues that recognize sphingosine 1 phosphate. J Biol Chem 2000;275:39379-39384.
94. Sardar VM, et al. Molecular basis for the lysophosphatidic acid receptor agonist selectivity. Biochim Biophys Acta 2002;1582:309-317.
95. Luo ZJ, Tanaka T, Kimura F, Miyasaka M. Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Immunopharmacology 1999;41:199-207.
96. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998;160:5493-5499.
97. Sprent J. Recirculating Lymphocytes. In: Marchalonis JJ, ed. The Lymphocyte, Structure and Function Volume Part 1. New York: Marcel Dekker, Inc. 1977, 43-114.
98. Goetzl EJ, An S. A subfamily of G protein-coupled cellular receptors for lysophospholipids and lysosphingolipids. Adv Exp Med Biol 1999;469:259-264.
99. + T cells. J Immmunol 2003;170:3662-3670.
100. Henning G, et al. CCR7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 2001;194:1875-1881.
101. Yagi H, et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000;30:1435-1444.
102. Lind EF, Prockop SE, Porritt HE, Petrie HT. Mapping precursor movement through the postnatal thymus reveals specific microenvironments supporting defined stages of early lymphoid development. J Exp Med 2001;194:127-134.
103. Poznansky MC, et al. Thymocyte emigration is mediated by active movement away from stroma-derived factors. J Clin Invest 2002;109:1101-1110.
104. Suzuki G, et al. Pertussis toxin-sensitive signal controls the trafficking of thymocytes across the corticomedullary junction in the thymus. J Immunol 1999;162:5981-5985.
105. Scollay RG, Butcher EC, Weissman IL. Thymus cell migration. Quantitative aspects of cellular traffic from the thymus to the periphery in mice. Eur J Immunol 1980;10:210-218.
106. Tough DF, Sprent J. Thymic emigration - a reply. Immunol Today 1995;16:273-274.
107. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med 1994;179:1127-113S.
108. Scollay R, Godfrey D1. Thymic emigration: conveyor belts or lucky dips? Immunol Today 1995;16:268-273.
109. - thymocytes and its implications in the late stage of thymocyte development. Immunology 1999;97:665-671.
110. + thymocytes in normal mouse thymus. Int Immunol 2000;13:313-320.
111. Nakayama T, et al. The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J Immunol 2002;168:87-94.
112. Feng C, et al. A potential role for CD69 in thymocyte emigration. Int Immunol 2002;14:535-544.
113. Chaffin KE, Perimutter RM. A pertussis toxin-sensitive process controls thymocyte emigration. Eur J Immunol 1991;21:2565-2573.
114. Miniati DN, Robbins RC. Heart transplantation: a thirty-year perspective. Annu Rev Med 2002;53:189-205.
115. DeMeo DL, Ginns LC. Lung transplantation at the turn of the century. Annu Rev Med 2001;52:185-201.
116. Klein M, Radhakrishnan J, Appel G. Cyclosporine treatment of glomerular disease. Annu Rev Med 1999;50:1-15.
117. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? Annu Rev Immunol 1998;16:619-644.